Proteon Therapeutics Announces First Quarter 2017 Financial Results
May 10, 2017 12:01 pm UTC| Business
WALTHAM, Mass., May 10, 2017 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today...
Proteon Therapeutics Announces First Quarter 2017 Financial Results
May 10, 2017 12:01 pm UTC| Business
WALTHAM, Mass., May 10, 2017 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today...
EIS to Use Microsoft Bot Framework to Deliver AI Services to Insurers
May 10, 2017 12:00 pm UTC| Business
SAN FRANCISCO, May 10, 2017 -- EIS Group, a leading provider of insurance core systems, today announced that the EIS Digital Experience Platform (DXP) has integrated with and is using Microsoft Bot Framework to deliver...
May 10, 2017 11:45 am UTC| Business
LOS ANGELES, May 10, 2017 -- Nova LifeStyle, Inc.(NASDAQ:NVFY) or (the “Company”), a U.S. based innovative provider of modern LifeStyle products and services, announced today that the Company intends to begin...
Kandi Technologies Reports First Quarter 2017 Financial Results
May 10, 2017 11:39 am UTC| Business
JINHUA, China, May 10, 2017 -- Kandi Technologies Group, Inc. (the “Company,” “we” or “Kandi”) (NASDAQ:KNDI), today announced its financial results for the first quarter of 2017. First Quarter Highlights Total...
Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
May 10, 2017 11:32 am UTC| Business
Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter Continued...
Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
May 10, 2017 11:32 am UTC| Business
Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter Continued...